Literature DB >> 8843312

In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species.

A L Barry1, S D Brown.   

Abstract

A new triazole derivative (voriconazole or UK-109,496) and fluconazole were tested against 249 isolates of Candida spp. representing six species. Voriconazole was 10 to 100 times more potent than fluconazole. Strains with decreased susceptibility to fluconazole were inhibited by relatively low concentrations of voriconazole.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8843312      PMCID： PMC163448     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  30 in total

1.  Trends in antifungal susceptibility among Candida sp. Urinary isolates from 1994 and 1998.

Authors:  J Baran; E Klauber; J Barczak; K Riederer; R Khatib
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  In vitro evaluation of voriconazole against some clinically important fungi.

Authors:  M R McGinnis; L Pasarell; D A Sutton; A W Fothergill; C R Cooper; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.

Authors:  M A Pfaller; D J Diekema; J H Rex; A Espinel-Ingroff; E M Johnson; D Andes; V Chaturvedi; M A Ghannoum; F C Odds; M G Rinaldi; D J Sheehan; P Troke; T J Walsh; D W Warnock
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

4.  Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis.

Authors:  W R Kirkpatrick; R K McAtee; A W Fothergill; M G Rinaldi; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

5.  In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa.

Authors:  M A Pfaller; J Zhang; S A Messer; M E Brandt; R A Hajjeh; C J Jessup; M Tumberland; E K Mbidde; M A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

6.  Activity of voriconazole, a new triazole, combined with neutrophils or monocytes against Candida albicans: effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor.

Authors:  S Vora; N Purimetla; E Brummer; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

7.  Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis.

Authors:  William R Kirkpatrick; Sofia Perea; Brent J Coco; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.

Authors:  L Purkins; N Wood; P Ghahramani; K Greenhalgh; M J Allen; D Kleinermans
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species.

Authors:  C J Clancy; M H Nguyen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-08       Impact factor: 3.267

10.  Stable phenotypic resistance of Candida species to amphotericin B conferred by preexposure to subinhibitory levels of azoles.

Authors:  J A Vazquez; M T Arganoza; D Boikov; S Yoon; J D Sobel; R A Akins
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.